Cantargia AB
STO:CANTA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.809
5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cantargia AB
Cantargia AB
Accrued Liabilities
Cantargia AB
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cantargia AB
STO:CANTA
|
Accrued Liabilities
kr23.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Accrued Liabilities
kr86.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Accrued Liabilities
kr190m
|
CAGR 3-Years
15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Accrued Liabilities
kr43m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cantargia AB
Glance View
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
See Also
What is Cantargia AB's Accrued Liabilities?
Accrued Liabilities
23.3m
SEK
Based on the financial report for Sep 30, 2024, Cantargia AB's Accrued Liabilities amounts to 23.3m SEK.
What is Cantargia AB's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
2%
Over the last year, the Accrued Liabilities growth was -20%. The average annual Accrued Liabilities growth rates for Cantargia AB have been -16% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
